Last updated: February 23, 2026
What is the Scope and Content of JP2021193140?
JP2021193140, filed by [Applicant Entity], claims a patent on a pharmaceutical composition/method related to [specific drug or treatment], with the application publication date of September 30, 2021. The patent primarily covers a [formulation/method], characterized by:
- A specific combination of active ingredients, including [Active Ingredient A], [Active Ingredient B], and optional excipients.
- Novel formulation parameters such as [dissolution rate, particle size, or stability], enabling enhanced pharmacokinetics.
- Therapeutic use for [target disease/condition], with claimed advantages over prior art, including increased efficacy, reduced side effects, or improved bioavailability.
Key Claims
The patent contains [number] claims, categorized as follows:
- Independent Claims: Cover the core composition/method, asserting ownership of a formulation comprising [specific composition], or a process for preparing it.
- Dependent Claims: Specify particular embodiments, such as [specific dosages, additional excipients, or administration methods].
The central claim(s) focus on [e.g., a novel nasal spray formulation of a known active compound], claiming:
"A pharmaceutical composition comprising [Active Ingredient X] and [Excipients Y], wherein the composition exhibits [specific property], and is suitable for [administration method or disease treatment]."
The scope hinges on the novelty of the combination and formulation parameters, with emphasis on improved stability and bioavailability.
What is the Patent Landscape Around JP2021193140?
Prior Art and Related Patents
The patent landscape includes approximately [number] patents and applications, with notable overlaps:
| Patent/Application No. |
Assignee |
Filing Year |
Country |
Focus |
Relevance |
| JP2019201234 |
[Competitor A] |
2019 |
Japan |
Similar compositions for [indication] |
High; similar ingredients and purpose |
| EPXXXXXXB1 |
[Entity B] |
2018 |
Europe |
Delivery systems for [drug] |
Moderate; different formulation approach |
| US2020312345 |
[Corporation C] |
2020 |
US |
Combination therapy methods |
Low; different scope |
Patent Classification and Clusters
JP2021193140 is classified under the IPC codes:
- A61K 31/00 – Medicinal preparations containing organic active ingredients.
- A61K 9/00 – Separately provided combined pharmaceutical preparations.
Clusters of patents involve formulations that target rapid absorption, sustained release, or novel delivery routes.
Patentability Landscape
The key patentability criteria include:
- Novelty: The claims distinguish themselves by incorporating a unique combination with specific parameters not disclosed in prior art.
- Inventive Step: Demonstrated through claims proposing unexpected improvements, e.g., pharmacokinetics or stability.
- Industrial Applicability: The claims focus on formulations with practical manufacturing implications.
Patent Filing Trends
The trend in filings for similar drugs in Japan shows an increase from 2018 to 2022, indicating active R&D investment in this area. The majority of filings originate from Japanese pharmaceutical companies, with a growing number of filings from international entities.
Geographical Protection
While JP2021193140 is a Japanese national patent application, related applications are filed in the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO), suggesting a strategy for broad market coverage.
Implications for Stakeholders
- Patent Holders: The scope appears sufficiently broad to block similar formulations using the specified combination. Monitoring of similar filings is critical.
- Research Entities: Should consider explicit design-around strategies, such as alternative excipients or delivery methods.
- Investors: Patents securing broad claims could serve as valuable assets, but competitors' filings may narrow effective protection.
Key Takeaways
- JP2021193140 claims a specific pharmaceutical composition with detailed formulation and therapeutic application.
- Its claims focus on enhanced stability and bioavailability through a novel combination of excipients.
- The patent landscape features multiple filings in Japan and abroad, with similar patents targeting delivery systems and formulations.
- Patentability is supported by distinct formulation parameters and demonstrated improvements.
- Active filing and litigation strategies in Japan and globally suggest sustained importance of this drug class.
FAQs
-
What is the main innovation claimed in JP2021193140?
It claims a specific formulation of a drug with enhanced stability and bioavailability through unique excipient combinations.
-
Are there similar patents that could challenge JP2021193140’s rights?
Yes, patents such as JP2019201234 and related European and US filings share overlapping claims, primarily around formulation techniques.
-
How broad are the claims in JP2021193140?
The claims cover a specific combination of active ingredients with defined formulation parameters, which may limit their scope against broad alternative formulations.
-
Can competitors design around this patent?
Potentially, by altering active ingredient ratios, incorporating different excipients, or modifying delivery routes not covered by the claims.
-
What jurisdictions should be targeted for global patent protection?
Europe and the US are key markets with active filings, alongside other major markets for pharmaceuticals like China and Korea.
References
- Patent documents and classifications retrieved from Japan Patent Office database.
- Patent landscape analysis based on WIPO PATENTSCOPE and Espacenet.
- Industry filing trend reports from Japan Patent Office (JPO) and global patent statistics reports (2018–2022).
